AMG-47a

Cat. No.: HY-18303

CAS No.: 882663-88-9

Molecular Formula: $C_{29}H_{28}F_3N_5O_2$

Molecular Weight: 535.56

Target: Src; VEGFR; p38 MAPK; JAK

Pathway: Protein Tyrosine Kinase/RTK; MAPK/ERK Pathway; Epigenetics; JAK/STAT Signaling; Stem Cell/Wnt

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 34 mg/mL (63.48 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Mass / Solvent / Concentration	1 mg	5 mg	10 mg
1 mM	1.8672 mL	9.3360 mL	18.6720 mL
5 mM	0.3734 mL	1.8672 mL	3.7344 mL
10 mM	0.1867 mL	0.9336 mL	1.8672 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

AMG-47a is a potent and orally active lymphocyte-specific protein tyrosine kinase (Lck) inhibitor, with an IC_{50} of 0.2 nM. AMG-47a also inhibits VEGF2, p38α, Jak3 and MLR and IL-2 with IC_{50}s of 1 nM, 3 nM, 72 nM, 30 nM and 21 nM, respectively. AMG-47a has anti-inflammatory activity[1].

IC_{50} & Target

IC50: 0.2 nM (Lck), 1 nM (VEGF2), 3 nM (p38α), 72 nM (Jak3), 30 nM (MLR), 21 nM (IL-2)[1]

CUSTOMER VALIDATION

- Oncogene. 2018 Aug;37(31):4226-4238.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Carver J, et al. A high-throughput assay for small molecule destabilizers of the KRAS oncoprotein. PLoS One. 2014 Aug 5;9(8):e103836.

[2]. Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem. 2006 Sep 21;49(19):5671-86.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA